MBX Biosciences, Inc. (MBX)
66.43
-0.33
(-0.49%)
USD |
NASDAQ |
Aug 27, 16:00
66.43
0.00 (0.00%)
After-Hours: 16:49
MBX Biosciences Enterprise Value : 2.786B for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 2.786B |
| August 25, 2026 | 2.875B |
| August 24, 2026 | 2.768B |
| August 21, 2026 | 2.765B |
| August 20, 2026 | 2.766B |
| August 19, 2026 | 2.865B |
| August 18, 2026 | 2.774B |
| August 17, 2026 | 2.857B |
| August 14, 2026 | 2.873B |
| August 13, 2026 | 2.801B |
| August 12, 2026 | 2.796B |
| August 11, 2026 | 2.750B |
| August 10, 2026 | 2.757B |
| August 07, 2026 | 2.837B |
| August 06, 2026 | 2.803B |
| August 05, 2026 | 2.820B |
| August 04, 2026 | 2.975B |
| August 03, 2026 | 2.673B |
| July 31, 2026 | 2.746B |
| July 30, 2026 | 2.772B |
| July 29, 2026 | 2.652B |
| July 28, 2026 | 2.465B |
| July 27, 2026 | 2.524B |
| July 24, 2026 | 2.558B |
| July 23, 2026 | 2.633B |
| Date | Value |
|---|---|
| July 22, 2026 | 2.380B |
| July 21, 2026 | 2.475B |
| July 20, 2026 | 2.468B |
| July 17, 2026 | 2.602B |
| July 16, 2026 | 2.381B |
| July 15, 2026 | 2.494B |
| July 14, 2026 | 2.298B |
| July 13, 2026 | 2.464B |
| July 10, 2026 | 2.512B |
| July 09, 2026 | 2.736B |
| July 08, 2026 | 2.545B |
| July 07, 2026 | 2.558B |
| July 06, 2026 | 2.351B |
| July 02, 2026 | 2.356B |
| July 01, 2026 | 2.266B |
| June 30, 2026 | 2.232B |
| June 29, 2026 | 2.122B |
| June 26, 2026 | 2.049B |
| June 25, 2026 | 1.957B |
| June 24, 2026 | 1.863B |
| June 23, 2026 | 1.767B |
| June 22, 2026 | 1.649B |
| June 18, 2026 | 1.608B |
| June 17, 2026 | 1.539B |
| June 16, 2026 | 1.468B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amylyx Pharmaceuticals, Inc. | 3.884B |
| ANI Pharmaceuticals, Inc. | 1.947B |
| Corcept Therapeutics, Inc. | 12.63B |
| Veru, Inc. | 24.63M |
| Johnson & Johnson | 678.50B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -37.10M |
| Total Expenses (Quarterly) | 37.10M |
| EPS Diluted (Quarterly) | -0.7777 |
| Earnings Yield | -3.62% |
| Normalized Earnings Yield | -3.623 |